Teleflex Incorporated (NYSE:TFX) Stock Has Consensus Target Price of $154.40

Teleflex Incorporated (NYSE:TFX) has been given an average recommendation of “Moderate Buy” by the twelve brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $154.40.

TFX has been the topic of a number of recent research reports. UBS Group boosted their target price on Teleflex from $145.00 to $158.00 and gave the company a “neutral” rating in a research note on Tuesday, August 11th. Zacks Research lowered Teleflex from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 23rd. Piper Sandler reaffirmed an “overweight” rating and set a $169.00 price target (up from $160.00) on shares of Teleflex in a research note on Friday, August 7th. Wall Street Zen upgraded Teleflex from a “sell” rating to a “hold” rating in a report on Sunday, August 9th. Finally, Truist Financial lowered their price target on Teleflex from $150.00 to $142.00 and set a “hold” rating for the company in a research note on Wednesday, October 14th.

Institutional Trading of Teleflex

A number of institutional investors have recently added to or reduced their stakes in TFX. GAMMA Investing LLC increased its holdings in shares of Teleflex by 9.8% during the 3rd quarter. GAMMA Investing LLC now owns 921 shares of the medical technology company’s stock valued at $115,000 after acquiring an additional 82 shares during the last quarter. Hsbc Holdings PLC raised its stake in Teleflex by 4.7% during the 1st quarter. Hsbc Holdings PLC now owns 1,861 shares of the medical technology company’s stock valued at $222,000 after purchasing an additional 84 shares during the last quarter. Baldwin Wealth Partners LLC MA raised its position in shares of Teleflex by 7.5% during the third quarter. Baldwin Wealth Partners LLC MA now owns 1,702 shares of the medical technology company’s stock valued at $213,000 after buying an additional 119 shares during the last quarter. Leonteq Securities AG raised its position in shares of Teleflex by 13.6% during the first quarter. Leonteq Securities AG now owns 1,164 shares of the medical technology company’s stock valued at $139,000 after buying an additional 139 shares during the last quarter. Finally, Sage Rhino Capital LLC lifted its stake in shares of Teleflex by 9.5% in the first quarter. Sage Rhino Capital LLC now owns 1,837 shares of the medical technology company’s stock valued at $220,000 after buying an additional 159 shares during the period. 95.62% of the stock is currently owned by institutional investors and hedge funds.

Teleflex Trading Up 7.0%

Shares of NYSE:TFX opened at $149.72 on Friday. The firm has a fifty day moving average of $131.62 and a two-hundred day moving average of $125.60. The company has a quick ratio of 2.12, a current ratio of 2.60 and a debt-to-equity ratio of 0.94. Teleflex has a 12-month low of $100.18 and a 12-month high of $150.04. The firm has a market capitalization of $6.34 billion, a P/E ratio of -6.43, a price-to-earnings-growth ratio of 0.94 and a beta of 0.85.

Teleflex (NYSE:TFX) last posted its quarterly earnings results on Thursday, August 6th. The medical technology company reported $1.76 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.48. Teleflex had a negative net margin of 39.67% and a positive return on equity of 11.93%. The business had revenue of $570.33 million for the quarter, compared to the consensus estimate of $559.59 million. During the same period in the prior year, the business posted $3.73 earnings per share. Teleflex’s revenue for the quarter was up 28.9% compared to the same quarter last year. On average, equities analysts expect that Teleflex will post 7.22 EPS for the current fiscal year.

About Teleflex

Teleflex Incorporated is a global medical technology company that develops, manufactures and markets specialty medical devices. Its products are designed to support healthcare professionals in critical care and procedural settings, including vascular access, interventional cardiology and radiology, anesthesia, respiratory care, emergency medicine, surgical applications and urology.

The company’s portfolio includes catheters, access and closure devices, airway-management products, surgical instruments, pain-management devices and other technologies used in hospitals and outpatient facilities.